Comparing two types of radiation therapy for prostate cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of ultra-hypofractionated radiation therapy compared to moderately hypofractionated radiation therapy, combined with high-dose-rate brachytherapy for prostate cancer. It involves a feasibility phase with 28 patients followed by a comparative cohort study. The study aims to assess toxicity, acceptability, and long-term survival outcomes while monitoring the precision of radiation delivery using advanced imaging techniques. The trial is conducted at the Centre intégré de cancérologie du CHU de Québec-Université Laval.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Biopsy proven Prostate adenocarcinoma
* Stage T1c, T2 (Annex 2)
* Stage Nx or N0
* Stage Mx or M0
* PSA \< 20ng/ml
* Gleason Score 6 or 7
* Having the ability to sing a written consent

Exclusion Criteria:

* Age \< 18ans
* Clinical Stage T3 or T4
* Stage N1
* Stage M1
* PSA \> 20
* Gleason Score 8 to 10
* IPSS Score \> 20 alpha-blocking medication.
* Prior pelvic radiotherapy.
* History of active collagenosis (Lupus, Sclerodermia, Dermatomyosis)
* Past history of Inflammatory Bowell Disease
* Bilateral hip prosthesis

Where it's running

• CHUdeQuebec
  Québec, Canada Recruiting

Study contacts

• Study coordinator: Andre-Guy Martin
• Email: andre-guy.martin.med@ssss.gouv.qc.ca
• Phone: 14186915264

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High Dose Rate Brachytherapy for Prostate Cancer Recurrence

  This study is testing if a special type of radiation treatment called High Dose Rate Brachytherapy can help men with prostate cancer that has come back after surgery feel better and have fewer side effects compared to regular radiation.

  Recruiting Clinica Universidad de Navarra, Universidad de Navarra · Pamplona, Foral Community of Navarre · NCT06982469

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• MRI-based microboost SBRT with de-escalated whole-gland radiation for localized prostate cancer

  This study tests whether giving a focused 45 Gy microboost to MRI-defined lesions with smaller whole-gland doses (30 or 35 Gy) is safe and effective for men with low- to intermediate-risk localized prostate cancer.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia · NCT07644598

• Short-term hormone therapy with PSMA PET/CT before prostate removal for high-risk localized prostate cancer

  This trial will test whether giving short-term androgen-deprivation therapy (ADT) before prostate removal lowers PSMA PET signal and helps predict recurrence risk in men with localized high-risk prostate cancer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT07455903

• Prostate-first versus combined prostate and pelvic lymph node radiation dose escalation in PSMA PET–staged node-positive prostate cancer

  This trial tests whether giving a stronger radiation boost to just the prostate first or to both the prostate and pelvic lymph nodes helps men whose prostate cancer has spread to nearby pelvic lymph nodes seen on PSMA PET.

  Recruiting Phase 2/3 Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07426094

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.